NHS Dudley Health Economy Medicines Formulary
Home > 10 Musculoskeletal and joint diseases > 10.1 Drugs used in rheumatic diseases and gout > 10.1.3 Drugs that suppress the rheumatic disease process > Rheumatoid arthritis (after failure of previous anti-rheumatic drugs) - golimumab - NICE TAG TA225

Rheumatoid arthritis (after failure of previous anti-rheumatic drugs) - golimumab - NICE TAG TA225

1.1 Golimumab in combination with methotrexate is recommended as an option for the treatment of rheumatoid arthritis in adults whose rheumatoid arthritis has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate, if:

  • it is used as described for other tumour necrosis factor (TNF) inhibitor treatments in 'Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (NICE technology appraisal guidance 130), and

  • the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose, agreed as part of the patient access scheme.

1.2 Golimumab in combination with methotrexate is recommended as an option for the treatment of rheumatoid arthritis in adults whose rheumatoid arthritis has responded inadequately to other DMARDs, including a TNF inhibitor, if:

  • it is used as described for other TNF inhibitor treatments in 'Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor' (NICE technology appraisal guidance 195), and

  • the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose, agreed as part of the patient access scheme.

1.3 When using the disease activity score (DAS28), healthcare professionals should take into account any physical, sensory or learning disabilities, communication difficulties, or disease characteristics that could adversely affect patient assessment and make any adjustments they consider appropriate.

 

https://www.nice.org.uk/guidance/TA225

Site by Devopa
© Copyright 2020 NHS. All rights reserved.